Dashboard
1
Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months
- Poor long term growth as Net Sales has grown by an annual rate of -50.27% and Operating profit at 6.19% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
Risky -
3
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
HKD 1,027 Million ()
NA (Loss Making)
NA
0.00%
-0.40
-999,999.00%
0.56
Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Jul 2010)
Net Profit:
0 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-16.44%
0%
-16.44%
6 Months
-17.57%
0%
-17.57%
1 Year
-39.8%
0%
-39.8%
2 Years
-76.33%
0%
-76.33%
3 Years
-71.36%
0%
-71.36%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Arrail Group Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-50.27%
EBIT Growth (5y)
6.19%
EBIT to Interest (avg)
-3.49
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
0.17
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.66
EV to EBIT
-141.05
EV to EBITDA
-162.17
EV to Capital Employed
0.44
EV to Sales
281.02
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-0.31%
ROE (Latest)
-0.13%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Bearish
Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jul'10 - YoY
Jul'10
Jul'09
Change(%)
Net Sales
0.60
0.30
100.00%
Operating Profit (PBDIT) excl Other Income
-0.50
-0.70
28.57%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.30
-0.70
57.14%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in quarter ended Jul 2010 is 100.00% vs -88.46% in Jul 2009
Consolidated Net Profit
YoY Growth in quarter ended Jul 2010 is 57.14% vs 22.22% in Jul 2009
Annual Results Snapshot (Consolidated) - Mar'23
Mar'23
Mar'22
Change(%)
Net Sales
1,685.00
1,969.40
-14.44%
Operating Profit (PBDIT) excl Other Income
56.20
292.70
-80.80%
Interest
50.60
67.50
-25.04%
Exceptional Items
23.00
-809.10
102.84%
Consolidate Net Profit
-255.40
-844.80
69.77%
Operating Profit Margin (Excl OI)
-144.10%
-3.10%
-14.10%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2023 is -14.44% vs 13.67% in Mar 2022
Consolidated Net Profit
YoY Growth in year ended Mar 2023 is 69.77% vs -23.60% in Mar 2022
About Arrail Group Ltd. 
Arrail Group Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






